Jinwu Financial News | Sinolink Securities research pointed out that Juzhi Bio (02367) recently announced on its official website that its bone repair material has been approved as a Class III medical instrument, meeting the expectations for obtaining the certificate in the previous prospectus for Q4 24. 1）Indications: Filling and repair of maxillofacial and alveolar bone defects; 2）Advantages: It can quickly shape without collapsing to provide support, and also has a high-efficiency repair function to guide bone regeneration; 3）Components: Inorganic component is hydroxyapatite particles, organic component is macromolecular polysaccharides.

The institution stated that the cosmetic line continues to improve its multi-product matrix, and the medical aesthetics are expected to take off next year. Considering the impressive online performance during Singles' Day Sales, the company's profit forecast has been raised, expecting adjusted net income of 2.09/2.55/3.06 billion yuan for 2024-2026 (previous values were 2.03/2.52/3.01 billion yuan), representing a year-on-year increase of 43%/22%/20%. The attributable net income is expected to be 2/2.46/2.97 billion yuan, with a year-on-year increase of 38%/23%/21%, corresponding to PE ratios of 25/20/17 times, maintaining a "Buy" rating.